Long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma-derived factor VIII (Koate) that contains ADAMTS13.

导出 LinkOut

翻译打印收藏纠错

第一作者： Tammuella,Chrisentery-Singleton

第一单位： American Thrombosis and Hemostasis Network, Rochester, New York, USA.

作者： Tammuella,Chrisentery-Singleton ^[1] ; Lisa N,Boggio ^[2] ; Manuel D,Carcao ^[3] ; Sami,Ibrahimi ^[4] ; Osman,Khan ^[5] ; Arash,Mahajerin ^[6] ; Anita,Rajasekhar ^[7] ; Vivek,Sharma ^[8] ; MacGregor,Steele ^[9] ; Marcela,Torres ^[10] ; Frank J,Rodino ^[11] ; Shannon L,Carpenter ^[12]

作者单位： American Thrombosis and Hemostasis Network, Rochester, New York, USA. ^[1] Ochsner Clinic Foundation, New Orleans, Louisiana, USA. ^[2] Rush Hemophilia & Thrombophilia Center, Rush University Medical Center, Chicago, Illinois, USA. ^[3] Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada. ^[4] OUHSC/Stephenson Cancer Center, Oklahoma City, Oklahoma, USA. ^[5] University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. ^[6] Children's Hospital of Orange County, Orange, California, USA. ^[7] University of Florida - Shands Hospital, Gainesville, Florida, USA. ^[8] University of Louisville, Louisville, Kentucky, USA. ^[9] Alberta Children's Hospital, Edmonton, AB, Canada. ^[10] Department of Hematology, Cook Children's Medical Center, Fort Worth, Texas, USA. ^[11] Churchill Outcomes Research, Red Bank, New Jersey, USA. ^[12] Children's Mercy Hospital, Kansas City, Missouri, USA. ^[13]

关键词 ADAMTS13 protein Upshaw-Schulman syndrome congenital thrombotic thrombocytopenic factor VIII/administration and dosage microangiopathic haemolytic anaemia paediatric prophylaxis purpura von Willebrand factor-cleaving protease